Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing cognitive and physical performance

• US 8,524,741 B2
• Filed: 07/09/2007
• Issued: 09/03/2013
• Est. Priority Date: 07/10/2006
• Status: Active Grant

• Current Assignee: Synapsin Pharmaceuticals Inc.
• Original Assignee: Synapsin Pharmaceuticals Inc.
• Inventors: Dorsey, Denis, Kindy, Mark S.
• Primary Examiner(s): HUI, SAN MING R
• Application Number:
  US12/307,459
• Publication Number:
  US 20100056572A1
• Time in Patent Office: 2,248 Days
• Field of Search: 514/315
• US Class Current: 514/315
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.

Claims

1. A method of treating a human subject diagnosed with Alzheimer'"'"'s disease, comprising administering to the human subject a therapeutically effective amount of a composition comprising a piperidine alkaloid, wherein the piperidine alkaloid comprises the formula

2. The method of claim 1, wherein the composition comprises an extract of fire ant (Solenopsis invicta) venom.

3. The method of claim 1, wherein the piperidine alkaloid is Solenopsin A.

4. The method of claim 1, wherein the piperidine alkaloid is selected from the group consisting of trans-2-methyl-6-undecylpiperidine, trans-2-methyl-6-tridecylpiperidine, and trans-2-methyl-6-pentadecylpiperidine.

5. The method of claim 4, wherein the piperidine alkaloid is trans-2-methyl-6-undecylpiperidine.

6. The method of claim 1, wherein the composition is administered to the subject orally, systemically, or intracranially.